

## Company Information Pack

### Corporate Details

**US Entity:**

RLS (USA) Inc.  
8345 NW 66<sup>th</sup> Street  
Suite 6479  
Miami, FL 33166  
United States

**South African Entity**

Cyclomedical (Pty) Ltd ta  
RLS South Africa  
Route 21 Corporate Park  
Irene  
0178  
South Africa

[www.rls.bio](http://www.rls.bio)  
[contact@rls.bio](mailto:contact@rls.bio)

### Board of Directors

**Werner Gruner**

Chief Executive Officer

**Jaco van Niekerk**

Senior Vice President  
Strategy & Business  
Development

**Dr. Gerdus Kemp**

Senior Vice President  
Chief Operating Officer

### Advisory Board

**Cathy S. Cutler, PhD**

Director  
Medical Isotope Research  
Production

### Business Overview

On January 18, 2019, RLS (USA) Inc. concluded an agreement to purchase and take full ownership of the GE HealthCare's (Medi-Physics, Inc) Radiopharmacy sites thereby acquiring:

- 31 GE Healthcare nuclear radiopharmacies (located across 18 States).
- 29 Years of investments by GE into this sector.
- Existing long-term supply agreements with 1,700 US hospitals.
- The distribution of over 2.7 million doses per year.
- Long term contracts with the US top 3 established GPO's (Group Purchasing Organizations).
- A recent completion of a 3-year substantial upgrade to the current pharmacies.
- State of the art equipment and infrastructure.
- The full complement of over 540 staff members that currently run the operation, who's wealth of experience and knowledge is second to none.
- RLS is deemed an official GE Channel Partner and has secured a long-term (10yrs min) relationship with GE that we see RLS as the market leader and innovator within this industry.
- Inheritance of all risk and compliance structures in force and effect currently. As well as the commitment in continuing to work with most third-party service providers.

### Vision

RLS aspires to be at the forefront of isotope production and delivery of service to the International Nuclear Medicine Market. RLS will continue the hard work done by GE in the constant manufacture and distribution of SPECT products as well as introducing PET products into the market.

RLS has invested substantially into this business as part of a long-term strategy and intend to establish, maintain and grow the supply of products into the nuclear medicine industry. RLS are also investing substantially in not only cementing the foundation of the nuclear medicine industry but we are looking to bring our wealth of knowledge and experience in revolutionizing the radiopharmaceutical industry and thus providing our clients with best and most up to date products and access to new technologies when we bring them to market.

### In Summary

RLS have seized the initiative in mapping out how we are going to revitalize and reenergize the nuclear medicine industry within the US. Together with GE Healthcare & Life Sciences we are going to optimize and streamline nuclear medicine for the foreseeable future while stimulating long awaited growth within the industry and thus creating opportunities for people looking to fulfil their passion to work within nuclear medicine industry.

## Summary Forecast

The following forecast has been modeled and structured around the inevitable introduction of the PET products and conservative growth in the existing SPECT network

### Forecast financial performance

*In million USD*

	Notes	'19	'20	'21	'22	'23	'24	'25
<b>Total Revenue*</b>		<b>220</b>	<b>276</b>	<b>344</b>	<b>419</b>	<b>475</b>	<b>550</b>	<b>627</b>
Revenue SPECT		220	250	292	340	396	462	539
Revenue PET			26	53	79	79	88	88
<b>Cost of Sales</b>		<b>152</b>	<b>183</b>	<b>221</b>	<b>263</b>	<b>296</b>	<b>338</b>	<b>380</b>
Cost of Sales SPECT		152	170	195	223	256	293	336
Cost of Sales PET		0	14	27	40	40	44	44
<b>Gross Profit</b>		<b>69</b>	<b>93</b>	<b>123</b>	<b>156</b>	<b>179</b>	<b>212</b>	<b>247</b>

## More Information about the background of RLS

The management team has existing businesses in South Africa as described below:

- PET Labs (South Africa) is owned and managed by Gerdus Kemp, who is a shareholder in the Company, which houses a commercial radiopharmaceutical manufacturing and distribution center, and is home to the first Siemens-CTI 11-MeV negative ion cyclotron with adjoining hot cells in Africa that support both commercial and research and development programs. PET Labs is the only Cyclotron facility in the private sector and supplies 80% of the South African Market with PET nuclear medicine.
- Klydon (Pty) Ltd is a private company that has business operations in the gas- and solar energy markets; as well as in the medical imaging field and in the development and production of pharmaceuticals. Klydon owns proprietary technology that is classified as dual-use technology and is registered in terms of the Nuclear Act of 1993 with the Council for Non-Proliferation of Weapons of Mass Destruction that operates in the Department of Trade and Industry. It is, furthermore, also registered with the International Atomic Energy Agency (IAEA) that is resident in Vienna. In addition, the company, via the relevant subsidiary companies, has several licenses and registrations with the Medical Control Council (MCC) and the Pharmacy Council to be able to operate in the medical imaging field and for the production of pharmaceuticals under Good Manufacturing Practice (GMP) protocol.



## RLS (USA) Inc – Credit Information

Parent Entity	US Entity	SA Entity
RLS Group Ltd Suite 205A, Saffrey Square Bay street, Nassau Bahamas P.O. Box N-9934	RLS (USA) Inc 8345 NW 66 <sup>TH</sup> Street Suite 6479 Miami, Florida 33166 United States	Cyclomedical (Pty) Ltd ta RLS South Africa Route 21 Corporate Park Irene 0178 South Africa

### Bank Reference:

Account Holder: RLS (USA) Inc,  
Bank: Bank of America  
Account number: 0046 6146 2177  
Contact Person: Upon Request

### Trade References

Lantheus Medical Imaging  
331 Treble Cove Road  
N. Billerica, MA 01862  
Contact No 1-800-362-2668

Mc Kesson  
6555 State Highway 161,  
Irving, Texas, 75039  
Contact No 1-972-446-4800

Pharmalucence, Inc.  
29 Dunham Road  
Billerica, MA 01821  
Contact 1-781-275-7120

### Financials

Please note that there are no consolidated financials available at this time due to the current standing of the business and in respect to the agreement that we have signed with GE Healthcare (Medi-Physics, Inc). As noted above, we have provided a high level 'Financial Forecast' summary to provide you with a base of our financial expectations and obligations over the next six years.

---

**John Chapman**

**m:** +01 (423) 292 0056  
**e:** jchapman@rls.bio  
**w:** rls.bio

## Pavon, Sandy

---

**From:** Forster, Sara  
**Sent:** Thursday, November 14, 2019 7:19 AM  
**To:** Song, Taehoon; Pavon, Sandy  
**Cc:** Tomczak, Tammy  
**Subject:** FW: RLS Information Pack  
**Attachments:** RLS Information pack V5.pdf

Good morning... Could you please scan in the attached document and this email message, and return to me. If the information sheets don't have a date on them, please use the message date, below.

This is additional information to Roush Industries, Inc. CN613919

---

**From:** Mark Elliott <melliott@rls.bio>  
**Sent:** Wednesday, November 13, 2019 6:31 AM  
**To:** Forster, Sara <Sara.Forster@nrc.gov>  
**Subject:** [External\_Sender] RLS Information Pack

Good morning Ms Forster,

Please find attached an information pack on RLS which will provide some context to the meeting this morning.

Look forward to meeting with you.

Regards,

Mark Elliott

RLS (USA) Inc.  
8345 NW 66th Street, Suite 6479  
Miami, FL 33166, United States

m: (423) 292-2071  
e: [melliott@rls.bio](mailto:melliott@rls.bio)  
w: [rls.bio](http://rls.bio)